Cognivia Secures €15.5M Funding to Revolutionize Drug Development
We are thrilled to announce a significant milestone in Cognivia’s journey towards reshaping pharmaceutical and biotech clinical research….
News
News
News
Cognivia Presenting at OARSI 2024
Arthur Ooghe, Data Mining & Statistical Research, will be presenting at this year’s OARSI 2024 conference. Join Arthur…
News
Announcing Upcoming Webinar: “Navigate Placebo Response: Insights and Mitigation Strategies for Clinical Excellence”
Cognivia is thrilled to announce its first webinar of 2024, a compelling panel discussion slated for April 29th,…
News
Cognivia CEO, Dominique Demolle, to Speak at Panel Discussion on Innovative Placebo Response Analysis in CNS Trials
Cognivia is thrilled to announce that Dominique Demolle, CEO of Cognivia, has been cordially invited to participate in…
News
Dominique Demolle to Unveil Cognivia AI-powered Innovations at DPharm Conference
Dominique Demolle, CEO of Cognivia, is set to deliver a captivating presentation at the upcoming DPharm conference which is scheduled for…
News
What the FDA’s Final Guidance on Covariates Means for Fighting the Placebo Response in RCTs: Our Article Published in ACRP Journal
The recently released final guidance by the U.S. Food & Drug Administration (FDA) on “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products” introduces a new framework that is poised to transform the way statistical analyses are conducted in RCTs.